China Fines Simcere Unit $3.7M Over Rabies Vaccines

Law360, New York (May 18, 2010, 1:14 PM EDT) -- Chinese generic-drug maker Simcere Pharmaceutical Group has confirmed that a Chinese safety authority fined one of its subunits 25.6 million yuan ($3.7 million) for selling “substandard” rabies vaccines.

The Changzhou Food and Drug Administration imposed the financial penalty on Simcere subsidiary Jiangsu Yanshen Biological Technology Stock Co. Ltd. over its production of substandard human rabies vaccines, Simcere said in a statement Monday.

The agency’s 25.6 million yuan fine is the result of penalties and confiscated revenues derived from selling the vaccines, Simcere said.

Jiangsu Yanshen will...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.